Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Christopher Y. Thomas"'
Autor:
Taylor C. Peak, Elena M. Fenu, Michael B. Rothberg, Christopher Y. Thomas, Ronald L. Davis, Edward A. Levine
Publikováno v:
Case Reports in Urology, Vol 2020 (2020)
Nivolumab plus ipilimumab represents an effective combination of checkpoint inhibitors that can lead to a durable response with minimal toxicity in patients with metastatic renal cell carcinoma (mRCC). We present a case of a pathologic complete respo
Externí odkaz:
https://doaj.org/article/3c5e560514ea4ba0b0ab5d50a2ebab91
Autor:
Christopher Y. Thomas, Snjezana Zaja-Milatovic, Nikole Varhegyi, Michael G. Douvas, Paula M. Fracasso, Christopher A. Moskaluk, Bethany J. Horton, Gina R. Petroni, Patrick M. Dillon
Purpose: Genetic and preclinical studies have implicated FGFR signaling in the pathogenesis of adenoid cystic carcinoma (ACC). Dovitinib, a suppressor of FGFR activity, may be active in ACC.Experimental Design: In a two-stage phase II study, 35 patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a5f9174364d8e9885de3a152a92f9e6
https://doi.org/10.1158/1078-0432.c.6526778
https://doi.org/10.1158/1078-0432.c.6526778
Autor:
Christopher Y. Thomas, Snjezana Zaja-Milatovic, Nikole Varhegyi, Michael G. Douvas, Paula M. Fracasso, Christopher A. Moskaluk, Bethany J. Horton, Gina R. Petroni, Patrick M. Dillon
Methodology and results for exploratory aims, FISH, IHC and quality of life. SUPPLEMENTAL FIGURE 1: Change point analysis including a second inflection point in calculation of average slope of 34 evaluable patients. Supplemental Figure 2: First, last
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1956e40fa9d3d7ff60ba7e76520560d1
https://doi.org/10.1158/1078-0432.22467902.v1
https://doi.org/10.1158/1078-0432.22467902.v1
Autor:
Shannon L. Golden, Angela Tatiana Alistar, Christopher Y. Thomas, Rodwige J. Desnoyers, Alexandra Thomas, Scott Isom, Stefan C. Grant, Patricia E. Gallagher, Rhonda L. Bitting, E. Ann Tallant, Katherine Pleasant, Heidi D. Klepin, Mark C. Chappell, W. Jeffrey Petty, Janet A. Tooze
Publikováno v:
Am J Clin Oncol
Objective Preclinical studies with muscadine grape extract (MGE) show antitumor activity and decreased systemic inflammation. This phase I study (NCT02583269) assessed safety and tolerability of a proprietary MGE preparation in patients with advanced
Autor:
Michael B. Rothberg, Taylor C. Peak, Elena M Fenu, Edward A. Levine, Christopher Y. Thomas, Ronald L. Davis
Publikováno v:
Case Reports in Urology, Vol 2020 (2020)
Case Reports in Urology
Case Reports in Urology
Nivolumab plus ipilimumab represents an effective combination of checkpoint inhibitors that can lead to a durable response with minimal toxicity in patients with metastatic renal cell carcinoma (mRCC). We present a case of a pathologic complete respo
Autor:
Christopher A. Moskaluk, Patrick M. Dillon, Nikole Varhegyi, Michael G. Douvas, Snjezana Zaja-Milatovic, Bethany J. Horton, Gina R. Petroni, Paula M. Fracasso, Christopher Y. Thomas
Publikováno v:
Clinical Cancer Research. 23:4138-4145
Purpose: Genetic and preclinical studies have implicated FGFR signaling in the pathogenesis of adenoid cystic carcinoma (ACC). Dovitinib, a suppressor of FGFR activity, may be active in ACC. Experimental Design: In a two-stage phase II study, 35 pati
Autor:
Janet A. Tooze, Morgan Neve, Jessica Brown, Michael Moses Goodman, Donald Charles Vile, Rhonda L. Bitting, Purnima Dubey, Christopher Y. Thomas, Mitra Kooshki, Pierre L. Triozzi
Publikováno v:
Journal of Clinical Oncology. 39:433-433
433 Background: Single agent checkpoint inhibition is effective in a small proportion of platinum-refractory UC patients but improvements are needed. UC is highly inflammatory, and low-dose chemotherapy may enhance the response to immunotherapy. We e
Autor:
Renata Ferrarotto, Ezra E.W. Cohen, Shanthi Marur, Bonnie S. Glisson, Jan Cosaert, Jennifer E. Tseng, Barbara A. Murphy, J. Jack Lee, William N. William, Nusrat Harun, Christopher Y. Thomas, Dong M. Shin, Richard Willey, Ignacio W. Wistuba, Robert I. Haddad
Publikováno v:
Oral oncology. 82
Objectives Cixutumumab (CIX) and cetuximab (CET) monoclonal antibodies block ligand-binding to insulin-like growth factor-1 receptor (IGF-1R) and epidermal growth factor receptor (EGFR) respectively. The objective of this study was to assess the effi
Autor:
Patrick M. Dillon, Samhita Chakraborty, Christopher A. Moskaluk, Christopher Y. Thomas, Prashant J. Joshi
Publikováno v:
Head & Neck. 38:620-627
Background Adenoid cystic carcinoma (ACC) is a rare tumor of secretory glands. In this study, recent advances in molecular characterization and in therapeutics are reviewed. Methods A search of articles in PubMed and of abstracts from national meetin
Autor:
Wennuan Liu, A. Karim Kader, Seong Tae Kim, Lars Egevad, Scott D. Cramer, Zheng Zhang, Christopher Y. Thomas, Patrick P. Koty, Jianfeng Xu, Zhong Wang, William B. Isaacs, Jishan Sun, Jielin Sun, Johan Lindberg, G. Steven Bova, Chunmei C. Xie, Henrik Grönberg, S. Lilly Zheng
Publikováno v:
Cancer. 119:2405-2412
BACKGROUND This study sought to identify novel effectors and markers of localized but potentially life-threatening prostate cancer (PCa), by evaluating chromosomal copy number alterations (CNAs) in tumors from patients who underwent prostatectomy and